MX2024005632A - Tratamiento de la depresion resistente al tratamiento con psilocibina. - Google Patents
Tratamiento de la depresion resistente al tratamiento con psilocibina.Info
- Publication number
- MX2024005632A MX2024005632A MX2024005632A MX2024005632A MX2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A MX 2024005632 A MX2024005632 A MX 2024005632A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- psilocybin
- resistant depression
- subject
- depression
- Prior art date
Links
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 title abstract 3
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 title abstract 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163277407P | 2021-11-09 | 2021-11-09 | |
| US202163284973P | 2021-12-01 | 2021-12-01 | |
| PCT/US2022/048713 WO2023086252A1 (en) | 2021-11-09 | 2022-11-02 | Treatment of treatment resistant depression with psilocybin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005632A true MX2024005632A (es) | 2024-07-29 |
Family
ID=84799979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005632A MX2024005632A (es) | 2021-11-09 | 2022-11-02 | Tratamiento de la depresion resistente al tratamiento con psilocibina. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250000881A1 (https=) |
| EP (1) | EP4429671A1 (https=) |
| JP (1) | JP2024543379A (https=) |
| KR (1) | KR20240110816A (https=) |
| AU (1) | AU2022387053A1 (https=) |
| CA (1) | CA3237885A1 (https=) |
| MX (1) | MX2024005632A (https=) |
| WO (1) | WO2023086252A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| TW202304466A (zh) * | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) * | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| GB2588505B (en) * | 2017-10-09 | 2022-08-03 | Compass Pathfinder Ltd | Preparation of psilocybin |
| US12377112B2 (en) * | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| TW202304466A (zh) * | 2021-03-30 | 2023-02-01 | 英商康派斯開拓者公司 | 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）組成物，其製備方法及使用方法 |
-
2022
- 2022-11-02 WO PCT/US2022/048713 patent/WO2023086252A1/en not_active Ceased
- 2022-11-02 MX MX2024005632A patent/MX2024005632A/es unknown
- 2022-11-02 US US18/703,950 patent/US20250000881A1/en active Pending
- 2022-11-02 JP JP2024527357A patent/JP2024543379A/ja active Pending
- 2022-11-02 CA CA3237885A patent/CA3237885A1/en active Pending
- 2022-11-02 EP EP22835920.4A patent/EP4429671A1/en active Pending
- 2022-11-02 AU AU2022387053A patent/AU2022387053A1/en active Pending
- 2022-11-02 KR KR1020247017950A patent/KR20240110816A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3237885A1 (en) | 2023-05-19 |
| EP4429671A1 (en) | 2024-09-18 |
| WO2023086252A1 (en) | 2023-05-19 |
| US20250000881A1 (en) | 2025-01-02 |
| KR20240110816A (ko) | 2024-07-16 |
| JP2024543379A (ja) | 2024-11-21 |
| AU2022387053A1 (en) | 2024-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005632A (es) | Tratamiento de la depresion resistente al tratamiento con psilocibina. | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| BR112021024310A2 (pt) | Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus | |
| CL2024003040A1 (es) | Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta | |
| BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| CL2018002734A1 (es) | Métodos de tratamiento con vitamina d | |
| CL2022002479A1 (es) | Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas | |
| AR120055A1 (es) | Métodos para tratar la enfermedad de fabry en pacientes que tienen insuficiencia renal | |
| WO2021211940A8 (en) | Methods for treating a complement mediated disorder caused by viruses | |
| CO2024012870A2 (es) | Tratamiento de neurofibromas cutáneos con mirdametinib | |
| ECSP22077573A (es) | Método para el tratamiento de afecciones asociadas a covid-19 | |
| CR20210514A (es) | USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183) | |
| PE20230996A1 (es) | Metodo para el tratamiento de afecciones asociadas a covid-19 | |
| MX2025014865A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib | |
| BR112022022599A2 (pt) | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma | |
| CL2021001976A1 (es) | Tratamiento de lesiones cutáneas y prurito en pacientes con prurigo nodular | |
| UY39673A (es) | Pauta posológica de sotorasib | |
| CO2022007501A2 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
| MX2021004463A (es) | Terapia de disminución de arginina para el tratamiento de la deficiencia de gamt. | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| BR112022013673A2 (pt) | Inibidores de ahr e seus usos |